Psychiatric and medical comorbidities of eating disorders: findings from a rapid review of the literature

Ashlea Hambleton1*, Genevieve Pepin2, Anvi Le3, Danielle Maloney1,4, National Eating Disorder Research Consortium, Stephen Touyz1,4 and Sarah Maguire1,4

Abstract

Background: Eating disorders (EDs) are potentially severe, complex, and life-threatening illnesses. The mortality rate of EDs is significantly elevated compared to other psychiatric conditions, primarily due to medical complications and suicide. The current rapid review aimed to summarise the literature and identify gaps in knowledge relating to any psychiatric and medical comorbidities of eating disorders.

Methods: This paper forms part of a rapid review) series scoping the evidence base for the field of EDs, conducted to inform the Australian National Eating Disorders Research and Translation Strategy 2021–2031, funded and released by the Australian Government. ScienceDirect, PubMed and Ovid/Medline were searched for English-language studies focused on the psychiatric and medical comorbidities of EDs, published between 2009 and 2021. High-level evidence such as meta-analyses, large population studies and Randomised Control Trials were prioritised.

Results: A total of 202 studies were included in this review, with 58% pertaining to psychiatric comorbidities and 42% to medical comorbidities. For EDs in general, the most prevalent psychiatric comorbidities were anxiety (up to 62%), mood (up to 54%) and substance use and post-traumatic stress disorders (similar comorbidity rates up to 27%). The review also noted associations between specific EDs and non-suicidal self-injury, personality disorders, and neurodevelopmental disorders. EDs were complicated by medical comorbidities across the neuroendocrine, skeletal, nutritional, gastrointestinal, dental, and reproductive systems. Medical comorbidities can precede, occur alongside or emerge as a complication of the ED.

Conclusions: This review provides a thorough overview of the comorbid psychiatric and medical conditions co-occurring with EDs. High psychiatric and medical comorbidity rates were observed in people with EDs, with comorbidities contributing to increased ED symptom severity, maintenance of some ED behaviours, and poorer functioning as well as treatment outcomes. Early identification and management of psychiatric and medical comorbidities in people with an ED may improve response to treatment and overall outcomes.

Keywords: Psychiatric, Medical, Comorbidities, Eating disorders

*Correspondence: ashlea.hambleton@sydney.edu.au

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Plain English Summary

The mortality rate of eating disorders is significantly elevated compared to other psychiatric conditions, primarily due to medical complications and suicide. Further, individuals with eating disorders often meet the diagnostic criteria of at least one comorbid psychiatric or medical disorder, that is, the individual simultaneously experiences both an ED and at least one other condition. This has significant consequences for researchers and health care providers – medical and psychiatric comorbidities impact ED symptoms and treatment effectiveness. The current review is part of a larger Rapid Review series conducted to inform the development of Australia’s National Eating Disorders Research and Translation Strategy 2021–2031. A Rapid Review is designed to comprehensively summarise a body of literature in a short timeframe, often to guide policymaking and address urgent health concerns. The Rapid Review synthesises the current evidence base and identifies gaps in eating disorder research and care. This paper gives a critical overview of the scientific literature relating to the psychiatric and medical comorbidities of eating disorders. It covers recent literature regarding psychiatric comorbidities including anxiety disorders, mood disorders, substance use disorders, trauma and personality disorders and neurodevelopmental disorders. Further, the review discusses the impact and associations between EDs and medical comorbidities, some of which precede the eating disorder, occur alongside, or as a consequence of the eating disorder.

Introduction

Eating Disorders (EDs) are often severe, complex, life-threatening illnesses with significant physiological and psychiatric impacts. EDs impact individuals across the entire lifespan, affecting all age groups (although most often they emerge in childhood and adolescence), genders, socioeconomic groups and cultures [1]. EDs have some of the highest mortality rates of all psychiatric illnesses and carry a significant personal, interpersonal, social and economic burdens [2, 3].

Adding to the innate complexity of EDs, it is not uncommon for people living with an ED to experience associated problems such as psychological, social, and functional limitations [2] in addition to psychiatric and medical comorbidities [4–6]. Comorbidity is defined as conditions or illnesses that occur concurrently to the ED. Evidence suggests that between 55 and 95% of people diagnosed with an ED will also experience a comorbid psychiatric disorder in their lifetime [4, 6]. Identifying psychiatric comorbidities is essential because of their potential impact on the severity of ED symptomatology, the individual’s distress and treatment effectiveness [7, 8].

The mortality rate of EDs is significantly higher than the general population, with the highest occurring in Anorexia Nervosa (AN) due to impacts on the cardiovascular system [9] and suicide. [10] Mortality rates are also heightened in Bulimia Nervosa (BN) and Other Specified Feeding and Eating Disorder (OSFED) [11]. Suicide rates are elevated across the ED spectrum, and higher rates are observed in patients with a comorbid psychiatric disorder [10, 12]. Of concern, the proportion of people with an ED not accessing treatment is estimated to be as high as 75% [13], potentially a consequence of comorbidities which impact on motivation, the ability to schedule appointments or require clinical prioritisation (i.e., self-harm or suicidal behaviours) [14]. Further, for many of those diagnosed with an ED who access treatment, recovery is a lengthy process. A longitudinal study found approximately two-thirds of participants with AN or BN had recovered by 22 years follow-up [15]. Although recovery occurred earlier for those with BN, illness duration was lengthy for both groups with quality of life and physical health impacts [15]. Further, less is known regarding the illness trajectory for those who do not receive treatment.

Medical comorbidities associated with EDs can range from mild to severe and life-threatening, with complications observed across all body systems, including the cardiac, metabolic and gastrointestinal, and reproductive systems [5]. These comorbidities and complications can place people at increased risk of medical instability and death [5]. Therefore, understanding how co-occurring medical comorbidities and complications impact EDs is critical to treatment and recovery.

In addition to ED-associated medical comorbidities, EDs often present alongside other psychiatric conditions. Psychiatric comorbidities in people with EDs are associated with higher health system costs, emergency department presentations and admissions [16]. Comorbidities may precede the onset of the ED, be co-occurring, or result from symptoms and behaviours associated with the ED [17, 18]. Individuals with an ED, their carers and care providers often face a complex and important dilemma; the individual with an ED requires treatment for their ED but also for their psychiatric comorbidities, and it can be difficult for treatment providers to determine which is the clinical priority [19]. This is further complicated by the fact that EDs and comorbidities may have a reciprocal relationship, whereby the presence of one impact the pathology, treatment and outcomes of the other.
The current Rapid Review (RR) forms part of a series of reviews commissioned by the Australian Federal Government to inform the Australian National Eating Disorders Research and Translation Strategy 2021–2031 [20]. In response to the impact of psychiatric and medical comorbidities on outcomes, this rapid review summarises the recent literature on the nature and implications of psychiatric and medical comorbidities associated with EDs.

**Methods**

The Australian Government Commonwealth Department of Health funded the InsideOut Institute for Eating Disorders (IOI) to develop the Australian Eating Disorders Research and Translation Strategy 2021–2031 [20] under the Psych Services for Hard to Reach Groups initiative (ID 4-8MSSLE). The strategy was developed in partnership with state and national stakeholders including clinicians, service providers, researchers, and experts by lived experience (both consumers and families/carers). Developed through a two-year national consultation and collaboration process, the strategy provides the roadmap to establishing EDs as a national research priority and is the first disorder-specific strategy to be developed in consultation with the National Mental Health Commission. To inform the strategy, IOI commissioned Health-care Management Advisors (HMA) to conduct a series of RRs to assess all available peer-reviewed literature on all DSM-5 listed EDs.

A RR Protocol [21] was utilised to allow swift synthesis of the evidence in order to guide public policy and decision-making [22]. This approach has been adopted by several leading health organisations including the World Health Organisation [17] and the Canadian Agency for Drugs and Technologies in Health Rapid Response Service [18], to build a strong evidence base in a timely and accelerated manner, without compromising quality. A RR is not designed to be as comprehensive as a systematic review—it is purposive rather than exhaustive and provides actionable evidence to guide health policy [23].

The RR is a narrative synthesis adhering to the PRISMA guidelines [24]. It is divided by topic area and presented as a series of papers. Three research databases were searched: ScienceDirect, PubMed and Ovid/Medline. To establish a broad understanding of the progress made in the field of EDs, and to capture the largest evidence base from the past 12 years (originally 2009–2019, but expanded to include the preceding two years), the eligibility criteria for included studies were kept broad. Therefore, included studies were published between 2009 and 2021, written in English, and conducted within Western healthcare systems or health systems comparable to Australia in terms of structure and resourcing. The initial search and review process was conducted by three reviewers between 5 December 2019 and 16 January 2020. The re-run for the years 2020–2021 was conducted by two reviewers at the end of May 2021.

The RR had a translational research focus with the objective of identifying evidence relevant to developing optimal care pathways. Searches therefore used a Population, Intervention, Comparison, Outcome (PICO) approach to identify literature relating to population impact, prevention and early intervention, treatment, and long-term outcomes. Purposive sampling focused on high-level evidence studies encompassing meta-analyses; systematic reviews; moderately sized randomised controlled studies (RCTs) (n > 50); moderately sized controlled-cohort studies (n > 50); and population studies (n > 500). However, the diagnoses ARFID and UFED necessitated less stringent eligibility criteria due to a paucity of published articles. As these diagnoses are newly captured in the DSM-5 (released in 2013, within the allocated search timeframe), the evidence base is still emerging, and few studies have been conducted. Thus, smaller studies (n ≤ 20) and narrative reviews were also considered and included. Grey literature, such as clinical or practice guidelines, protocol papers (without results) and Masters’ theses or dissertations, were excluded. Other sources (which may not be replicable when applying the current methodology) included the personal libraries of authors, yielding two additional studies (see Additional file 1). This extra step was conducted in line with the PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews [25].

Full methodological details including eligibility criteria, search strategy and terms and data analysis are published in a separate protocol paper, which included a total of 1320 studies [26] (see Additional file 1: Fig. S1 for PRISMA flow diagram). Data from included studies relating to psychiatric and medical comorbidities of EDs were synthesised and are presented in the current review. No further analyses were conducted.

**Results**

The search included articles published in the period January 2009 to May 2021. The RR identified 202 studies for inclusion. Of these, 58% related to psychiatric comorbidities (n = 117) and 42% to medical comorbidities (n = 85). A full list of the studies included in this review and information about population, aims and results can be found in Additional file 2: Tables S3, S4. Results are subdivided into two categories: (1) psychiatric comorbidities and (2) medical complications. Tables 1 and 2 provide high-level summaries of the results.
Table 1 Summary of results for psychiatric comorbidities included in the rapid review

| Psychiatric comorbidity | Summary |
|-------------------------|---------|
| Anxiety disorders (5 studies) | Anxiety disorders are most frequently comorbid condition reported in large population studies [8, 27]. Anxiety disorders often precede onset of EDs [28]. Temperamental factors specifically, anxiety sensitivity and experiential avoidance [29] appear to be associated with anxiety disorder and ED comorbidity. |
| Generalised anxiety disorder (GAD) (2 studies) | Noted evidence of a potential genetic link between EDs and GAD; the presence of one significantly increases the likelihood of the other [8, 30]. There were particular links between fasting, excessive exercise, low BMI and comorbid GAD [30]. |
| Social anxiety (4 studies) | Elevated rates of social anxiety across all ED diagnoses; highest in bulimia nervosa (BN), followed by binge eating disorder (BED) and AN-BP (AN—binge—purge subtype). Social anxiety was associated with more severe ED psychopathology and higher body weight [31] and acts as a barrier to accessing ED treatment [32]. |
| Obsessive compulsive disorder (OCD) (5 studies) | The reported comorbidity rates of OCD and EDs were variable [33]. There is symptom overlap between OCD and EDs [34], with evidence of OCD being related to more severe ED [34], and treatment of one condition associated with symptom improvement in the other [35]. Further, comorbidity of OCD and EDs appears to be maintained by intrusive thoughts and perfectionism [36]. |
| Major depressive disorder (MDD)/depression (10 studies) | Disordered eating may develop concurrently with depressive symptoms. Changes in frontal brain circuits seen in Depression, are also observed in EDs [37]. There is a strong relationship between MDD and EDs [AN, BN, BED and night eating syndrome (NES)]. However, results were mixed regarding the impact of MDD-ED comorbidity on treatment outcomes. |
| Bipolar disorder (BD) (11 studies) | Notable rates of comorbidity between BD and EDs were reported, however evidence about the frequency of this association was mixed, ranging between 1.9% to as high as 35.8% [38–40]. BD was seen most in EDs which consist of a binge and/or purge symptom profile and comorbidity appears to impact on ED symptom severity, poorer daily and neuropsychological functioning. |
| Personality disorders (PDs) (9 studies) | The association between any type of ED and PDs, was significantly higher than the general population [41]. For specific PDs, the proportions of paranoid, borderline, avoidant, dependant and obsessive—compulsive PD were significantly higher in EDs than the general population. The comorbidity between particular EDs and PDs appeared to be associated with common traits [i.e., impulsiveness of BN with borderline personality disorder (BPD), rigidity of AN with obsessive compulsive personality disorder (OCPD)]. Comorbidity was associated with greater distress and poorer outcomes [41, 42]. |
| Substance use disorders (SUD) (5 studies) | The prevalence rates of substance use in EDs were higher than the general population. Alcohol, caffeine and tobacco were the most frequently reported substances used in ED populations [43]. SUD was more frequently comorbid among individuals with binge/purge type EDs [44]. |
| Psychosis and schizophrenia (3 studies) | A limited area of research; the majority focussed on NES—12% of participants with schizophrenia also met criteria for NES [45]. The actual comorbidity between psychotic disorders and ED remains unclear. |
| Body dysmorphic disorder (BDD) (5 studies) | AN and BDD share similar psychopathology and both have a peak onset period in adolescence, although BDD development typically precedes AN [46]. The prevalence rates of BDD among individuals with AN are variable, however BDD contributes to greater symptom severity in individuals with AN. |
| Attention deficit hyperactivity disorder (ADHD) (9 studies) | A positive association between ADHD and disordered eating, particularly between overeating and ADHD [47]. A twofold increased risk of ADHD in individuals with an ED [48] and studies have noted particularly strong associations between ADHD and ED [49, 50]. Children with ADHD were more like to experience an ED or binge, purge, or engage in restrictive behaviours above clinical threshold [51]. |
| Autism spectrum disorder (ASD) (4 studies) | Prevalence rates of ASD are reported to be as high as 22.9% among individuals with EDs, compared with 2% observed in the general population [52]. There is a high level of symptom cross-over between EDs and ASD. Symptoms of ASD are frequently exhibited by patients with AN [53, 54]. An assessment of common phenomena between ARFID and ASD in children found a shared symptom profile of eating difficulties, behavioural problems and sensory hypersensitivity beyond what is observed in children without ASD [55]. |
| Post traumatic stress disorder (PTSD) (3 studies) | A broad range of prevalence rates between PTSD and EDs have been reported; between 16.1–22.7% for AN, 32.4–66.2% for BN and 24.02–31.6% for BED [56]. EDs might have a functional role to manage PTSD symptoms and reduce negative affect [57]. |
Table 1 (continued)

| Psychiatric comorbidity | Summary |
|-------------------------|---------|
| Suicidality (22 studies) | Suicide is one of the leading causes of death for individuals with EDs [58]. EDs were a significant risk factor for suicide, and evidence suggested a genetic association between the two [59, 60]. The risk for suicide attempts was higher for those with BN compared to other EDs, however, the risk of death by suicide was highest in AN [61, 62]. |
| Non-suicidal self-injury (NSSI) (7 studies) | Up to one-third of patients with EDs report NSSI at some stage in their lifetime, with over one quarter having engaged in NSSI within the previous year [63]. Higher levels of impulsivity and emotional reactivity among patients with EDs were associated with concurrent NSSI [64, 65]. There were significant differences in the prevalence of NSSI across ED diagnoses, although patients with binge/purge subtype EDs were more likely to engage in poly-NSSI [66]. |

Table 2 Summary of results for medical comorbidities included in the rapid review

| Medical Comorbidity | Summary |
|---------------------|---------|
| Cardiovascular Complications (4 studies) | AN has attracted the most research focus given its increased risk of cardiac failure due to severe malnutrition, dehydration and electrolyte imbalances [67]. Mitral valve prolapse impacted in 25% of patients, sinus bradycardia was the most common arrhythmia, pericardial effusion prevalence rates ranged from 15% to 30% [68]. The risk of cardiac arrest, arrhythmias and heart failure was higher in males with AN than females with AN [69]. |
| Cancer (1 study) | An area of limited research. One study noted a worse prognosis with higher mortality rates for individuals with EDs from melanoma, cancers of genital organs and cancers of unspecified sites. However, there was no statistically significant difference in cancer risk compared to the general population [70]. |
| Gastrointestinal disorders (GI) (14 studies) | More than 90% of AN patients report fullness, early satiety, abdominal distention, pain and nausea [68]. The actual cause of the increased prevalence of GI disorders and their contribution to ED maintenance remain poorly understood. |
| Bone health (16 studies) | The RR found evidence for bone loss/poor bone mineral density (BMD) and EDs, particularly in AN. The negative impacts of bone loss are more pronounced in individuals with early-onset AN when the skeleton is still developing [67] and among those who have very low BMI [71], with comorbidity rates as high as 46.9% [71]. However, lowered BMD was also observed among patients with BN [72]. |
| Refeeding syndrome (RFS) (20 studies) | Identified studies focused on individuals admitted to an inpatient unit for restrictive EDs. Noted variable prevalence rates of RFS [73] ranging from 0% to 62% [74]. Some studies noted that the provision of higher caloric feeds led to faster recoveries and shorter admission duration; with no incidence of RFS [75–77]. However, more research is required to establish best practice in this space including high quality RCTs in inpatient samples, and controlling for feeding methods (i.e. NG vs oral feeding). |
| Metabolic syndrome (11 studies) | Most research regarding metabolic syndrome has been among patients with BN, BED and NES. Both BN and BED have increased risk for type 2 diabetes [78]. The results suggested importance of increased monitoring and treatment of type 2 diabetes in individuals with EDs, particularly BED and NES. |
| Oral health (7 studies) | Despite ED patients reporting an increased concern for dental issues and engaging in more frequent oral hygiene, their oral health was worse [79]; with increased risk of dental erosion, periodontal disease, missing teeth and oral mucosal lesions [80, 81]. |
| Vitamin deficiencies (6 studies) | The impact of prolonged malnutrition in early-onset EDs can also impair brain development, substantially reducing neurocognitive function in younger patients even after weight restoration [82]. |
| Cognitive functioning (1 study) | Some cognitive functions affected (attention, decision making, memory) by EDs recover following nutritional restoration [83]. |
| Reproductive health (9 studies) | Infertility and higher rates of poor reproductive health are strongly associated with EDs, including miscarriages, induced abortions, obstetric complications, and poorer birth outcomes [84, 85]. Amenorrhea is a known consequence of AN, oligomenorrhea (irregular periods) was common among individuals with BN and BED [86]. Further, the RR found higher rates of Poly Cystic Ovarian Syndrome (PCOS), premenstrual syndrome (PMS), and premenstrual dysphoric disorder (PMDD) among the ED population compared to the general population [59, 60]. |

ADHD attention deficit hyperactivity disorder, AN anorexia nervosa, AN-BP anorexia nervosa–predominantly binge/purge subtype, AN-R anorexia nervosa—predominantly restrictive subtype, ASD autism spectrum disorder, BED binge eating disorder, BMI body mass index, BDD body dysmorphic disorder, BN bulimia nervosa, GI gastrointestinal disorders, GAD generalised anxiety disorder, MD major depressive disorder, NES night eating syndrome, NSSI Non suicidal self injury, OCD obsessive compulsive disorder, PCOS polycystic ovarian syndrome, PMS premenstrual syndrome, PMDD premenstrual dysphoric disorder, PTSD post traumatic stress disorder, RFS refeeding syndrome, SUD substance use disorder
Psychiatric comorbidities
The study of psychiatric comorbidities can assist with developing models of ED aetiology,conceptualising psychopathology and has relevance for treatment development and outcomes. Given that common psychological factors are observed across psychiatric disorders [87], it is not surprising that there are high prevalence rates of co-occurring psychiatric conditions with EDs. Comorbidity rates of EDs and other psychiatric conditions are elevated further in ethnic/racial minority groups [88]. When looking at the evidence from studies conducted with children and young people, one study of children with ARFID found that 53% of the population had a lifetime comorbid psychiatric disorder [89]. It emerged from the RR that research regarding psychiatric comorbidities generally focussed on the prevalence rates of comorbidities among certain ED subgroups, with some also exploring implications for treatment and ED psychopathology.

Anxiety disorders
Research indicates that EDs and anxiety disorders frequently co-occur [8, 27]. The high prevalence rates of anxiety disorders in the general population are also observed in people with EDs; with a large population study finding anxiety disorders were the most frequently comorbid conditions reported [8]. In a study of women presenting for ED treatment, 65% also met the criteria for at least one comorbid anxiety disorder [28]. Of note, 69% of those endorsing the comorbidity also reported that the anxiety disorder preceded the onset of the ED [28]. Another study explored anxiety across individuals with an ED categorised by three weight ranges (individuals whose weight is in the ‘healthy weight’ range, individuals in the ‘overweight’ range and individuals in the ‘obese’ range). While anxiety was elevated across all groups, the authors did note that individuals in the overweight group reported significantly higher rates of anxiety than individuals within the healthy weight group [90]. One study that explored temperamental factors provided some insight into factors that may mediate this association; anxiety sensitivity (a predictor of anxiety disorders) was associated with greater ED severity among individuals in a residential ED treatment facility [29]. Further, this association was mediated by a tendency to engage in experiential avoidance—the authors noting that individuals with greater ED symptoms were more likely to avoid distressing experiences [29].

Generalised anxiety disorder (GAD)
Studies have noted the potential genetic links between EDs and GAD, noting that the presence of one significantly increases the likelihood of the other [8, 30]. Further, there appears to be a relationship between the severity of ED behaviours and the co-occurrence of GAD, with comorbidity more likely when fasting and excessive exercise are present, as well as a lower BMI [30]. The authors noted the particularly pernicious comorbidity of EDs (specifically AN) and GAD may be amplified by the jointly anxiolytic and weight loss effects of food restriction and excessive exercise [30].

Social anxiety
A meta-analysis of 12 studies found higher rates of social anxiety across all ED diagnoses, with patients with BN demonstrating the highest rate of comorbidity at 84.5%, followed by both BED and AN-BP both at 75% [31]. High levels of social anxiety were also associated with more severe ED psychopathology [31] and higher body weight [91]. This particular comorbidity may also impact on access to treatment for the ED; a large follow-up study of adolescents found that self-reported social phobia predicted not seeking treatment for BN symptoms [32]. Interestingly, two studies noted that anxiety symptoms improved following psychological treatments that targeted ED symptoms, possibly due to a shared symptom profile [29, 31].

Obsessive–compulsive disorder
Similarities between the symptoms of Obsessive–Compulsive Disorder (OCD) and EDs, such as cognitive rigidity, obsessiveness, detail focus, perfectionism and compulsive routines have long been reported in the literature [34]. Given the symptom overlap, a meta-analysis sought to clarify the lifetime and current (that is, a current diagnosis at the time of data collection) comorbidity rates of OCD and EDs, noting the lifetime comorbidity rate was 18% and current comorbidity rate was 15% [33]. However, the authors noted that this prevalence may double over longer periods of observation, with some follow-up data demonstrating comorbidity rates of 33% [33]. Prevalence rates of OCD seemed to be highest among people with AN (lifetime = 19% and current = 14%) compared to other ED subtypes. In addition to the symptom crossover, this RR found evidence of a complex relationship between OCD and EDs, including a potential association between OCD and greater ED severity [34].

Network analysis found that doubts about simple everyday things and repeating things over and over bridged between ED and OCD symptoms. Further, a pathway was observed between restricting and checking compulsions and food rigidity as well as binge eating and hoarding. However, as the data was cross-sectional, directional inferences could not be made [36]. An earlier study explored how changes in OCD symptoms impact ED symptoms among an inpatient sample [35]. As was
hypothesised, decreases in OCD symptoms accounted for significant variance in decreases in ED symptoms, and this effect was strongest among ED patients with comorbid OCD. The study also found that irrespective of whether patients had comorbid OCD or not, when ED symptoms improved, so did symptoms of OCD [35]. The authors concluded that perhaps there is a reciprocal relationship between OCD and ED symptoms, whereby symptoms of both conditions interact in a synergistic, bidirectional manner, meaning that improvement in one domain can lead to improvement in another [35]. These findings were somewhat supported in a study by Simpson and colleagues (2013), which found exposure and response prevention (a specialised OCD treatment) resulted in a significant reduction in OCD severity, as was expected, and an improvement in ED symptoms. In their study, individuals with BN showed more improvement than those with AN—nevertheless, BMI still increased among those underweight [92].

Mood disorders

Depression and major depressive disorder (MDD)

This RR also found high levels of comorbidity between major depression and EDs. A longitudinal study of disordered eating behaviours among adolescents found that disordered eating behaviours and depressive symptoms developed concurrently [37]. Among the sample, over half the adolescent sample had a depressive disorder. Prevalence rates were similar for AN (51.5%) and BN (54%) [37]. The study also explored the neurological predictors of comorbid depression in individuals with EDs, noting that lower grey matter volumes in the medial orbitofrontal, dorsomedial, and dorsolateral prefrontal cortices predicted the concurrent development of purging and depressive symptoms [37]. The results suggested that alterations in frontal brain circuits were part of a neural aetiology common to EDs and depression [37].

This RR found much support for a strong relationship between depression and ED symptomatology. In a study of patients with AN, comorbid MDD was associated with a greater AN symptom severity [93], and this relationship between the symptoms of MDD and AN was bidirectional in a study of adolescents undergoing treatment for AN, whereby dietary restraint predicted increased guilt and hostility (symptoms of low mood) and fear predicted further food restriction [94]. Further studies noted the association between BN, BED and NES, with a higher prevalence of depression and more significant depression symptoms [95–97]. However, other studies have failed to find support for this association—for example, a Swedish twin study found no association between NES and other mental health disorders [98].

The impact of the relationship between depression and EDs on treatment outcomes was variable across the studies identified by the RR. One study noted the impact of depression on attrition; patients with BN and comorbid depression attending a university clinic had the highest rates of treatment drop-out [99]. However, in a sample of patients with AN, the comorbidity of depression (or lack of) did not impact treatment outcome and the severity of depression was not associated with changes in ED symptoms [100]. This finding was supported in another study of inpatients with AN; pre-treatment depression level did not predict treatment outcome or BMI [101].

Bipolar disorders

Notable comorbidity rates between bipolar disorders (BD) and EDs were reported in the literature reviewed, however evidence about the frequency of this association was mixed. Studies noted comorbidity rates of BD and EDs ranging between 1.9% to as high as 35.8% [38–40]. In order to better understand the nature of comorbidity, a recent systematic review and meta-analysis found BD (including bipolar 1 disorder and bipolar 2 disorder) and ED comorbidity varied across different ED diagnostic groups (BED—12.5%, BN—7.4%, AN—3.8%) [102]. However, the authors noted the scant longitudinal studies available, particularly in paediatric samples. An analysis of comorbidity within a sample of patients with BD identified that 27% of participants also met criteria for an ED; 15% had BN, 12% had BED, and 0.2% had AN [103]. Two other studies noted considerable comorbidity rates of BD: 18.6% for binge eating [104] and 8.8% for NES [105]. Some studies suggested the co-occurrence of BD and EDs were seen most in people with AN-BP, BN and BED—all of which share a binge and/or purge symptom profile [38, 106]. Specifically, BED and BN were the most common co-occurring EDs with BD [40], however, these EDs are also the most prevalent in the population. Therefore, it is unclear if this finding is reflective of the increased prevalence of BN and BED, or if it reflects a shared underlying psychopathology between BD and these EDs [40].

Comorbid ED-BD patients appear to experience increased ED symptom severity, poorer daily and neuropsychological functioning than patients with only a ED or BD diagnosis [107]. In an effort to understand which shared features in ED-BD relate to quality of life, one study assessed an adult sample with BD [108]. Binge eating, restriction, overevaluation of weight and shape, purging and driven exercise were associated with poorer clinical outcomes, quality of life and mood regulation [108]. Additionally, a study of patients undergoing treatment for BD noted patients with a comorbid ED had significantly poorer clinical outcomes and higher scores of depression [109]. Further, quality of life was significantly
lower among patients with comorbid ED-BD [109]. The comorbidity of ED and BD has implications for intervention and clinical management, as at least one study observed higher rates of alcohol abuse and suicidality among patients with comorbid ED and BD compared to those with BD only [40].

Personality disorders
This RR identified limited research regarding the comorbidity between personality disorders (PD) and EDs. A meta-analysis sought to summarise the proportion of comorbid PDs among patients with AN and BN [41]. There was a heightened association between any type of ED and PDs, and this was significantly different to the general population. For specific PDs, the proportions of paranoid, borderline, avoidant, dependant and obsessive–compulsive PD were significantly higher in EDs than in the general population. For both AN and BN, Cluster C PDs (avoidant, dependant and obsessive–compulsive) were most frequent. The authors noted that the specific comorbidity between specific EDs and PDs appears to be associated with common traits—constriction/perfectionism and rigidity is present in both AN and obsessive–compulsive PD (which had a heightened association), as was the case with impulsivity, a characteristic of both BN and borderline PD [41]. This symptom association was also observed in a study of adolescents admitted to an ED inpatient unit whereby a significant interaction between binge-purge EDs (AN-BP and BN), childhood emotional abuse (a risk factor for PD) and borderline personality style was found [110].

This comorbidity may be associated with greater patient distress and have implications for patient outcomes [41, 42]. Data from a nine-year observational study of individuals with BN reported that comorbidity with a PD was strongly associated with elevated mortality risk [111]. In terms of treatment outcomes, an RCT compared the one- and three-year treatment outcomes of four subgroups of women with BN, defined by PD complexity; no comorbid PD (health control), personality difficulties, simple PD and complex PD [112]. At pre-treatment, the complex PD group had greater ED psychopathology than the other three groups. Despite this initial difference, there were no differences in outcomes between groups at one-year and three-year follow up [112]. The authors suggested this result could be due to the targeting of the shared symptoms of BN and PD by the intervention delivered in this study, and that as ED symptoms improve, so do PD symptoms [112]. Suggesting that beyond symptom overlap, perhaps some symptoms attributed to the PD are better explained by the ED. This was consistent with Brietzke and colleagues’ (2011) recommendation that for individuals with ED and a comorbid PD, treatment approaches should target both conditions where possible [113].

Substance use disorders
Comorbid substance use disorders (SUDs) are also often noted in the literature as an issue that complicates treatment and outcomes of EDs [114]. A meta-analysis reported the lifetime prevalence of EDs and comorbid SUD was 27.9%, [43] with a lifetime prevalence of comorbid illicit drug use of 17.2% for AN and 18.6% for BN [115]. Alcohol, caffeine and tobacco were the most frequently reported comorbidities [43]. Further analysis of SUDs by substance type in a population-based sample indicated that the lifetime prevalence of an alcohol use disorder among individuals with AN was 22.4% [115]. For BN, the prevalence rate was slightly higher at 24.0% [115].

The comorbidity of SUD is considered far more common among individuals with binge/purge type EDs, evidenced by a meta-analysis finding higher rates of comorbid SUD among patients with AN-BP and BN than AN-R [44]. This trend was also observed in population data [116]. Further, a multi-site study found that patients with BN had higher rates of comorbid SUD than patients with AN, BED and Eating Disorder Not Otherwise Specific (EDNOS) (utilised DSM-IV criteria) [117]. Behaviourally, there was an association between higher frequencies of binge/purge behaviours with high rates of substance use [117]. The higher risk of substance abuse among patients with binge/purge symptomology was also associated with younger age of binge eating onset [118]. A study explored whether BN and ED subtypes with binge/purge symptoms predicted adverse outcomes and found that adolescent girls with purging disorder were significantly more likely to use drugs or frequently binge drink [119]. This association was again observed in a network analysis of college students, whereby there was an association between binge drinking and increased ED cognitions [120].

Psychosis and schizophrenia
The RR identified a small body of literature with mixed results regarding the comorbidity of ED and psychosis-spectrum symptoms. A study of patients with schizophrenia found that 12% of participants met full diagnostic criteria for NES, with a further 10% meeting partial criteria [45]. Miotto and colleagues’ (2010) study noted higher rates of paranoid ideation and psychotic symptoms in ED patients than those observed in healthy controls [121]. However, the authors concluded that these symptoms were better explained by the participant’s ED diagnosis than a psychotic disorder [121]. At a large population level, an English national survey noted associations...
between psychotic-like experiences and uncontrolled eating, food dominance and potential EDs [122]. In particular, these associations were stronger in males [122]. However, the true comorbidity between psychotic disorders and ED remains unclear and further research is needed.

**Body dysmorphic disorder**

While body image disturbances common to AN, BN and BED are primarily related to weight and shape concerns, individuals with body dysmorphic disorder (BDD) have additional concerns regarding other aspects of their appearance, such as facial features and skin blemishes [46, 123]. AN and BDD share similar psychopathology and both have a peak onset period in adolescence, although BDD development typically precedes AN [46]. The prevalence rates of BDD among individuals with AN are variable. In one clinical sample of female AN patients, 26% met BDD diagnostic criteria [124]. However, much higher rates were observed in another clinical sample of adults with AN, where 62% of patients reported clinically significant ‘dysmorphic concern’ [125].

As the RR has found with other mental health comorbidities, BDD contributes to greater symptom severity in individuals with AN, making the disorder more difficult to treat. However, some research suggested that improved long-term outcomes from treatments for AN are associated with the integration of strategies that address dysmorphic concerns [124, 126]. However, there remains little research on the similarities, differences and co-occurrence of BDD and AN, and with even less research on the cooccurrence of BDD and other EDs.

**Neurodevelopmental disorders**

**Attention deficit hyperactivity disorder**

Several studies noted the comorbidity between Attention Deficit Hyperactivity Disorder (ADHD) and EDs. A systematic review found moderate evidence for a positive association between ADHD and disordered eating, particularly between overeating and ADHD [47]. The impulsivity symptoms of ADHD were particularly associated with BN for all genders, and weaker evidence was found for the association between hyperactivity and restrictive EDs (AN and ARFID) for males, but not females [47]. Another meta-analysis reported a two-fold increased risk of ADHD in individuals with an ED [48] and studies have noted particularly strong associations between ADHD and BN [49, 50]. In a cohort of adults with a diagnosis of an ED, 31.3% had a ‘possible’ ADHD [127]. Another study considered sex differences; women with ADHD had a significantly higher lifetime prevalence of both AN and BN than women without ADHD [128]. Further, the comorbidity rates for BED were considerably higher among individuals with ADHD for both genders [128].

Further evidence for a significant association between ADHD and EDs was reported in a population study of children [51]. Results revealed that children with ADHD were more likely to experience an ED or binge, purge, or restrictive behaviours above clinical threshold [51]. Another study of children with ADHD considered gender differences; boys with ADHD had a greater risk of binge eating than girls [129]. However, the study found no significant difference in AN’s prevalence between ADHD and non-ADHD groups. Further, among patients attending an ED specialist clinic, those with comorbid ADHD symptoms had poorer outcomes at one-year follow-up [130].

**Autism spectrum disorder**

There is evidence of heightened prevalence rates of autism spectrum disorder (ASD) among individuals with EDs. A systematic review found an average prevalence of ASD with EDs of 22.9% compared with 2% observed in the general population [52]. With regards to AN, several studies have found symptoms of ASD to be frequently exhibited by patients with AN [53, 54]. An assessment of common phenomena between ARFID and ASD in children found a shared symptom profile of eating difficulties, behavioural problems and sensory hypersensitivity beyond what is observed in typically developing children (the control group) [55]. While research in this area is developing, the findings indicated these comorbidities would likely have implications for the treatment and management of both conditions [55].

**Post traumatic stress disorder**

Many individuals with EDs report historical traumatic experiences, and for a proportion of the population, symptoms of post traumatic stress disorder (PTSD). A broad range of prevalence rates between PTSD and EDs have been reported; between 16.1–22.7% for AN, 32.4–66.2% for BN and 24.02–31.6% for BED [56]. A review noted self-criticism, low self-worth, guilt, shame, depression, anxiety, emotion dysregulation, anger and impulsivity were linked to the association between EDs and trauma [57]. It was suggested that for individuals with trauma/PTSD, EDs might have a functional role to manage PTSD symptoms and reduce negative affect [57]. Further, some ED behaviours such as restriction, binge eating, and purging may be used to avoid hyperarousal, in turn maintaining the association between EDs and PTSD [57].

Few studies have explored the impact of comorbid PTSD on ED treatment outcomes. A study of inpatients admitted to a residential ED treatment service
investigated whether PTSD diagnosis at admission was associated with symptom changes [56]. Cognitive and behavioural symptoms related to the ED had decreased at discharge, however, they increased again at six-month follow up. In contrast, while PTSD diagnosis was associated with higher baseline ED symptoms, it was not related to symptom change throughout treatment or treatment dropout [56]. Given previous research identified that PTSD and EDs tend to relate to more complex courses of illness, greater rates of drop out and poorer outcomes, a study by Brewerton and colleagues [131], explored the presence of EDs in patients with PTSD admitted to a residential setting. Results showed that patients with PTSD had significantly higher scores of ED psychopathology, as well as depression, anxiety and quality of life. [131]. Further, those with PTSD had a greater tendency for binge-type EDs.

Suicidality
Suicide is one of the leading causes of death for individuals with EDs [58]. In a longitudinal study of adolescents, almost one quarter had attempted suicide, and 65% reported suicidal ideation within the past 6 months [37]. EDs are a significant risk factor for suicide, with some evidence suggesting a genetic association between suicide risk and EDs [59, 60]. This association was supported in the analysis of Swedish population registry data, which found that individuals with a sibling with an ED had an increased risk of suicide attempts with an odds ratio of 1.4 (relative cohort n = 1,680,658) [61]. For suicide attempts, this study found an even higher odds ratio of 5.28 (relative cohort n = 2,268,786) for individuals with an ED and 5.39 (relative cohort n = 1,919,114) for death by suicide [61]. A comparison of individuals with AN and BN indicated that risk for suicide attempts was higher for those with BN compared to AN [61]. However, the opposite was true for death by suicide, which was higher in AN compared to BN [61]. This result is consistent with the findings of a meta-analysis—the incidence of suicide was higher among patients with AN compared to those with BN or BED [62].

The higher incidence of suicide in adults with AN [132] is potentially explained by the findings from Guillaume and colleagues (2011), which suggested that comparative to BN, AN patients are more likely to have more serious suicide attempts resulting in a higher risk of death [133]. However, death by suicide remains a significant risk for both diagnoses. As an example, Udo and colleagues (2019) study reported that suicide attempts were more common in those with an AN-BP subtype (44.1%) than AN-R (15.7%), or BN (31.4%) [134]. Further, in a large cohort of transgender college students with EDs, rates of past-year suicidal ideation (a significant risk factor for suicide attempts) was 75.2%, and suicide attempts were 74.8%, significantly higher than cisgender students with EDs and transgender students without EDs [135]. The RR found that the risk of suicidal ideation and behaviour was associated with ED diagnosis and the presence of other comorbidities. Among a community-based sample of female college students diagnosed with an ED, 25.6% reported suicidal ideation, and this was positively correlated with depression, anxiety and purging [136]. In support of this evidence, Sagiv and Gvion (2020) proposed a dual pathway model of risk of suicide attempt in individuals with ED, which implicates trait impulsivity and comorbid depression [137]. In two large transdiagnostic ED patient samples, suicidal ideation was associated with different aspects of self-image between ED diagnoses. For example, suicidal ideation was associated with higher levels of self-blame among individuals with BED, while among patients with AN and OSFED, increased suicidal ideation was associated with a lack of self-love [138, 139].

Anorexia nervosa
Amongst adults with AN, higher rates of suicide have been reported amongst those with a binge-purge subtype (25%) than restrictive subtype (8.65%) [58, 140]. Further, comorbid depression and prolonged starvation were strongly associated with elevated suicide attempts for both subtypes [58, 140]. In another study, the risk of attempted suicide was associated with depression, but it was moderated by hospital treatment [93]. Further, suicidal ideation was related to depression. A significant ‘acquired’ suicide risk in individuals with AN has been identified by Selby et al. (2010) through an increased tolerance for pain and discomfort resultant from repeated exposure to painful restricting and purging behaviours [141].

Bulimia nervosa
Further research among individuals diagnosed with BN found an increased level of suicide risk [142]. Results from an extensive study of women with BN indicated that the lifetime prevalence of suicide attempts in this cohort was 26.9% [143]. In one study of individuals diagnosed with severe BN, 60% of deaths were attributed to suicide [144]. The mean age at the time of death was 29.6 years, and predictive factors included previous suicide attempts and low BMI. Further, in a sample of children and adolescents aged 7 to 18 years, higher rates of suicidal ideation were associated with BN, self-induced vomiting and a history of trauma [12].

A large population-based study of adolescents and adults explored the frequency and correlates of suicidal ideation and attempts in those who met the criteria for BN [145]. Suicidal ideation was highest in adolescents
with BN (53%), followed by BED (34.4%), other non-ED psychopathology (21.3%) or no psychopathology (3.8%). A similar trend was observed for suicide plans and attempts [145]. However, for adults, suicidality was more prevalent in the BN group compared to no psychopathology, but not statistically different to the AN, BED or other psychopathology groups [145].

Consistent with Crow and colleagues’ (2014) results, in a sample of women with BN, depression had the strongest association with lifetime suicide attempts [146]. There were also associations between identity problems, cognitive dysregulation, anxiousness, insecure attachment and lifetime suicide attempts among the sample. Depression was the most pertinent association, suggesting that potential comorbid depression should be a focus of assessment and treatment among individuals with BN due to the elevated suicide risk for this group [146]. Insecure attachment is associated with childhood trauma, and a systematic review found that suicide attempts in women with BN were significantly associated with childhood abuse and familial history of EDs [58].

**Binge eating disorder**

The RR found mixed evidence for the association between suicidal behaviour and BED. A meta-analysis found no suicides for patients with BED [62]. However, evidence from two separate large national surveys found that a significant proportion of individuals who had a suicide attempt also had a diagnosis of BED [134, 147].

**Non-suicidal self injury**

Non-suicidal self-injury (NSSI), broadly defined, is the intentional harm inflicted to one’s body without intent to die [148]. Recognising NSSI is often a precursor for suicidal ideation and behaviour [149], together with the already heightened mortality rate for EDs, several studies have examined the association between EDs and NSSI. Up to one-third of patients with EDs report NSSI at some stage in their lifetime, with over one quarter having engaged in NSSI within the previous year [63]. Similarly, a cohort study [148] found elevated rates of historical NSSI amongst patients with DSM-IV EDs; specifically EDNOS (49%), BN (41%) and AN (26%). In a Spanish sample of ED patients, the most prevalent form of NSSI was banging (64.6%) and cutting (56.9%) [63].

Further research has explored the individual factors associated with heightened rates of NSSI. Higher levels of impulsivity among patients with EDs have been associated with concomitant NSSI [64]. This was demonstrated in a longitudinal study of female students, whereby NSSI preceded purging, marking it a potential risk factor for ED onset [65]. In a study of a large clinical sample of patients with EDs and co-occurring NSSI, significantly higher levels of emotional reactivity were observed [150]. The highest levels of emotional reactivity were reported by individuals with a diagnosis of BN, who were also more likely to engage in NSSI than those with AN [150]. In Olatunji and colleagues’ (2015) cohort study, NSSI was used to regulate difficult emotions, much like other ED behaviours. NSSI functioning as a means to manage negative affect associated with EDs was further supported by Muehlenkamp and colleagues’ [66] study exploring the risk factors in inpatients admitted for an ED. The authors found significant differences in the prevalence of NSSI across ED diagnoses, although patients with binge/purge subtype EDs were more likely to engage in poly-NSSI (multiple types of NSSI). Consistent with these findings, a study of patients admitted to an ED inpatient unit found that 45% of patients displayed at least one type of NSSI [151]. The function of NSSI among ED patients was explored in two studies, one noting that avoiding or suppressing negative feelings was the most frequently reported reason for NSSI [151]. The other analysed a series of interviews and self-report questionnaires and found patients with ED and comorbid Borderline Personality Disorder (BPD) engaged in NSSI as a means of emotion regulation [152].

**Medical comorbidities**

The impact of EDs on physical health and the consequential medical comorbidities has been a focus of research. Many studies reported medical comorbidities resulting from prolonged malnutrition, as well as excessive exercise, binging and purging behaviours.

**Cardiovascular complications**

As discussed above, although suicide is a significant contributor to the mortality rate of EDs, physical and medical complications remain the primary cause of death, particularly in AN, with a high proportion of deaths thought to result from cardiovascular complications [153]. AN has attracted the most research focus given its increased risk of cardiac failure due to severe malnutrition, dehydration and electrolyte imbalances [67]. Cardiovascular complications in AN can be divided by conduction, structural and ischemic diseases. A review found that up to 87% of patients experience cardiovascular compromise shortly following onset of AN [153]. Within conduction disease, bradycardia and QT prolongation occur at a high frequency, largely due to low body weight and resultant decreased venous return to the heart. Whereas, atrioventricular block and ventricular arrhythmia are more rare [153]. Various structural cardiomyopathies are observed in AN, such as low left ventricular mass index (occurs frequently), mitral prolapse and pericardial effusion (occurs moderately). Ischemic
diseases such as dyslipidemia or acute myocardial infarction are more rare.

Another review identified cardiopulmonary abnormalities that are frequently observed in AN; mitral valve prolapse occurred in 25% of patients, sinus bradycardia was the most common arrhythmia, and pericardial effusion prevalence rates ranged from 15 to 30%. [68] Sudden cardiac death is thought to occur due to increased QT interval dispersion and heart rate variability. [68] A review of an inpatient database in a large retrospective cohort study found that coronary artery disease (CAD) was lower in AN patients than the general population (4.4% and 18.4%, respectively). Consistent with trends in the general population, the risk of cardiac arrest, arrhythmias and heart failure was higher in males with AN than females with AN [69].

Cancer
Given that individuals with AN have compromised biology, may avoid medical care, and have higher rates of substance use, research has examined cancer incidence and prognosis among individuals with AN. A retrospective study noted higher mortality from melanoma, cancers of genital organs and cancers of unspecified sites among individuals with AN, however, there was no statistically significant difference compared to the general population [70]. No further studies of cancer in EDs were identified.

Gastrointestinal disorders
The gastrointestinal (GI) system plays a pivotal role in the development, maintenance, and treatment outcomes for EDs, with changes and implications present throughout the GI tract. More than 90% of AN patients report fullness, early satiety, abdominal distention, pain and nausea [68]. Although it is well understood that GI system complaints are complicated and exacerbated by malnutrition, purging and binge eating [154, 155], the actual cause of the increased prevalence of GI disorders and their contribution to ED maintenance remain poorly understood.

To this end, a review aimed to determine the GI symptoms reported in two restrictive disorders (AN and ARFID), as well as the physiologic changes as a result of malnutrition and function of low body weight and the contribution of GI diseases to the disordered eating observed in AN and ARFID [156]. The review found mixed evidence regarding whether GI issues were increased in patients with AN and ARFID. This was partly due to the relatively limited amount of research in this area and mixed results across the literature. The review noted that patients with AN and ARFID reported a higher frequency of symptoms of gastroparesis. Further, there was evidence for a bidirectional relationship between AN and functional gastrointestinal disorders (FGIDs) contributing to ongoing disordered eating. The review found that GI symptoms observed in EDs develop due to (1) poorly treated medical conditions with GI-predominant symptoms, (2) the physiological and anatomical changes that develop due to malnutrition or (3) FGIDs.

There was a high rate of comorbidity (93%) between ED and FGIDs, including oesophageal, bowel and anorectal disorders, in a patient sample with AN, BN and EDNOS [157]. A retrospective study investigating increased rates of oesophageal cancer in individuals with a history of EDs could not conclude that risk was associated with purging over other confounding factors such as alcohol abuse and smoking [158].

Given that gut peptides like ghrelin, cholecystokinin (CCK), peptide tyrosine (PYY) and glucagon-like peptide 1 (GLP-1) are known to influence food intake, attention has focussed on the dysregulation of gut peptide signalling in EDs [159]. A review aimed to discuss how these peptides or the signals triggered by their release are dysregulated in EDs and whether they are normalised following weight restoration or weight loss (in the case of people with higher body weight) [159]. The results were inconsistent, with significant variability in peptide dysregulation observed across EDs [159]. A systematic review and meta-analysis explored whether ghrelin is increased in restrictive AN. The review found that all forms of ghrelin were raised in AN's acute state during fasting [160]. In addition, the data did not support differences in ghrelin levels between AN subtypes [160]. Another study examined levels of orexigenic ghrelin and anorexigenic peptide YY (PYY) in young females with ARFID, AN and healthy controls (HC) [161]. Results demonstrated that fasting and postprandial ghrelin were lower in ARFID than AN, but there was no difference between ARFID and AN for fasting and postprandial PYY [161].

Oesophageal and gastrointestinal dysfunction have been observed in patients with AN and complicate nutritional and refeeding interventions [155]. Findings from a systematic review indicated that structural changes that occurred in the GI tract of patients with AN impacted their ability to swallow and absorb nutrients [162]. Interestingly, no differences in the severity of gastrointestinal symptoms were observed between AN-R and AN-BP subtypes [155].

A systematic review of thirteen studies aimed to identify the most effective treatment approaches for GI disorders and AN [163]. An improvement in at least one or more GI symptoms was reported in 11 of the 13 studies, with all studies including nutritional rehabilitation, and half also included concurrent psychological treatment.
were mixed. However, the outcomes of these studies [169, 173]; other hormonal treatment [174–177] and oral contraceptives [169–172]; bisphosphonates replacement [169, 170]. Treatments include oestrogen therapy trials, mainly investigating the efficacy of hormone replacement [169, 170]. Treatments include oestrogen and oral contraceptives [169–172]; bisphosphonates [169, 173]; other hormonal treatment [174–177] and vitamin D [178]. However, the outcomes of these studies were mixed.

Bone health
The RR found evidence for bone loss/poor bone mineral density (BMD) and EDs, particularly in AN. The high rates of bone resorption observed in patients with AN is a consequence of chronic malnutrition leading to osteoporosis (weak and brittle bones), increased fracture risk and scoliosis [166]. The negative impacts of bone loss are more pronounced in individuals with early-onset AN when the skeleton is still developing [67] and among those who have very low BMI [71], with comorbidity rates as high as 46.9% [71]. However, lowered BMD was also observed among patients with BN [72].

A review [167] explored the prevalence and differences in pathophysiology of osteoporosis and fractures in patients with AN-R and AN-BP. AN-R patients had a higher prevalence of osteoporosis, and AN-BP patients had a higher prevalence of osteopenia (loss of BMD) [167]. Further, the authors noted the significant increase in fracture risk that starts at disease onset and lasts throughout AN, with some evidence that risk remains increased beyond remission and recovery [167]. Findings from a longitudinal study of female patients with a history of adolescent AN found long-term bone thinning at five and ten-year follow-up despite these patients achieving weight restoration [168].

Given this, treatment to increase BMD in individuals with AN has been the objective of many pharmacotherapy trials, mainly investigating the efficacy of hormone replacement [169, 170]. Treatments include oestrogen and oral contraceptives [169–172]; bisphosphonates [169, 173]; other hormonal treatment [174–177] and vitamin D [178]. However, the outcomes of these studies were mixed.

Refeeding syndrome
Nutritional rehabilitation of severely malnourished individuals is central to routine care and medical stabilisation of patients with EDs [179]. Within inpatient treatment settings, reversing severe malnutrition is achieved using oral, or nasogastric tube feeding. However, following a period of starvation, initiating/commencing feeding has been associated with ‘refeeding syndrome’ (RFS), a potentially fatal electrolyte imbalance caused by the body’s response to introducing nutritional restoration [180, 181]. The studies identified in the RR focused predominantly on restrictive EDs on this population group—results regarding RFS risk were mixed [73].

A retrospective cohort study of inpatients diagnosed with AN with a very low BMI implemented a nasogastric feeding routine with vitamin, potassium and phosphate supplementation [182]. All patients achieved a significant increase in body weight. None developed RFS [182], suggesting that even with extreme undernutrition, cautious feeding within a specialised unit can be done safely without RFS. For adults with AN, aminotransferases are often high upon admission, however are normalised following four weeks of enteral feeding [183, 184]. Further, the RR identified several studies demonstrating the provision of a higher caloric diet at intake to adolescents with AN led to faster recoveries and fewer days in the hospital with no observed increased risk for RFS [75–77]. These findings were also noted in a study of adults with AN [179].

However, the prevalence of RFS among inpatients is highly variable, with one systematic review noting rates ranging from 0 to 62% [74]. This variability was largely a reflection of the different definitions of RFS used across the literature [74]. A retrospective review of medical records of patients with AN admitted to Intensive Care Units (ICUs) aimed to evaluate complications, particularly RFS, that occurred during the ICU stay and the impact of these complications on treatment outcomes [185]. Of the 68 patients (62 female), seven developed RFS (10.3%) [185].

Although easily detectable and treatable, hypophosphatemia (a low serum phosphate concentration) may lead to RFS which is the term used to describe severe fluid and electrolyte shifts that can occur when nutrition support is introduced after a period of starvation. Untreated hypophosphatemia may lead to characteristic signs of the RFS such as respiratory failure, heart failure, and seizures [76, 179, 186–188]. A retrospective case–control study of inpatients with severe AN identified [189]. A retrospective study of AN and atypical AN patients undergoing refeeding found that the risk of hypophosphatemia was associated with a higher level of total weight loss and recent weight loss rather than the patient’s weight at admission [190]. The safe and effective use of prophylactic phosphate supplementation during refeeding was supported by the results from Agostino...
and colleagues’ chart review study [191], where 90% of inpatients received supplementation during admission. Higher calorie refeeding approaches are considered safe in most cases, however the steps necessitated to monitor health status are costly to health services [192]. The most cost-effective approach would likely involve prophylactic electrolyte supplementation in addition to high calorie refeeding, which would decrease the need for daily laboratory monitoring as well as shortening hospital stays [75, 191, 192]. A systematic review noted that much of the research regarding refeeding, particularly in children and young people, has been limited by small sample sizes, single-site studies and heterogeneous designs [181]. Further, the differing definitions of RFS, recovery, remission and outcomes leading to variable results. While RFS appears safe for many people requiring feeding, the risk and benefits of it are unclear [193] due to the limited research on this topic. Following current clinical practice guidelines on the safe introduction of nutrition is recommended.

Metabolic syndrome
Metabolic syndrome refers to a group of factors that increase risks for heart disease, diabetes, stroke and other related conditions [194]. Metabolic syndrome is conceptualised as five key criteria; (1) elevated waist circumference, (2) elevated triglyceride levels, (3) reduced HDL-C, (4) elevated blood pressure and (5) elevated fasting glucose. The binge eating behaviours exhibited in BN, BED and NES have been linked to the higher rates of metabolic syndrome observed in these ED patients [78, 195].

An analysis of population data of medical comorbidities with BED noted the strongest associations were with diabetes and circulatory systems, likely indexing components of metabolic syndrome [196]. While type 1 diabetes is considered a risk factor for ED development, both BN and BED have increased risk for type 2 diabetes [78]. A 16-year observation study found that the risk of type 2 diabetes was significantly increased in male patients with BED compared to the community controls [78]. By the end of the observation period, 33% of patients with BED had developed type 2 diabetes compared to 1.7% of the control group. The prevalence of type 2 diabetes among patients with BN was also slightly elevated at 4.4% [78]. Importantly, the authors were not able to control for BMI in this study. In another study, BED was the most prevalent ED in a cohort of type 2 diabetes patients [197]. Conversely, the prevalence of AN among patients with type 2 diabetes is significantly lower, with a review of national data reporting comorbidity rates to be 0.06% [198].

Metabolic dysfunction was observed in a relatively large sample of individuals with NES, including metabolic syndrome and type 2 diabetes, with women reporting slightly higher rates (13%) than men (11%) [199]. In another group of adults with type 2 diabetes, 7% met the diagnostic criteria for NES [200]. These findings suggested a need for increased monitoring and treatment of type 2 diabetes in individuals with EDs, particularly BED and NES. Another study found BED had a significant impact on metabolic abnormalities, including elevated cholesterol and poor glycaemic control [201].

The RR identified one intervention study, which examined an intervention to address medical comorbidities associated with BN and BED [195]. The study compared cognitive behaviour therapy (CBT) to an exercise and nutrition intervention to increase physical fitness, decrease body fat percentage and reduce the risk for metabolic syndrome. While the exercise intervention improved participants’ physical fitness and body composition, neither group reduced cardiovascular risk at one-year follow-up [195].

Oral health
Purging behaviour, particularly self-induced vomiting, has been associated with several oral health and gastrointestinal dysfunctions in patients with EDs. A case–control study of ED patients with binge/purge symptomology found that despite ED patients reporting an increased concern for dental issues and engaging in more frequent brushing, their oral health was poorer than controls. [79] Further, a systematic review and meta-analysis aimed to explore whether EDs increase the risk of tooth erosion [80]. The analysis found that patients with EDs had more risk of dental erosion, especially among those who self-induced vomiting [80]. These findings were also found in a large cohort study, where the increased risk for BN was associated with higher rates of dental erosion but not dental cavities [81].

However, a systematic review of 10 studies suggested that poor oral health may be common among ED patients irrespective of whether self-induced vomiting forms part of their psychopathology [202]. One study reported that AN-R patients had poorer oral health outcomes and tooth decay than BN patients [203]. Two studies identified associations between NES and poor oral health, including higher rates of missing teeth, periodontal disease [204, 205]. Another study of a group of patients with AN, BN and EDNOS, demonstrated the impact of ED behaviours on dental soft tissue, whereby 94% of patients had oral mucosal lesions, and 3% were found to have dental erosion [206].

Vitamin deficiencies
The prolonged periods of starvation, food restriction (of caloric intake and/or food groups), purging and excessive exercise observed across the ED spectrum have
detrimental impacts on micronutrient balances [207]. The impact of prolonged vitamin deficiencies in early-onset EDs can also impair brain development, substantially reducing neurocognitive function in some younger patients even after weight restoration [82]. Common micronutrient deficiencies include calcium, fat soluble vitamins, essential fatty acids selenium, zinc and B vitamins [183]. One included study looked at prevalence rates of cerebral atrophy and neurological conditions, specifically Wernicke’s encephalopathy in EDs and found that these neurological conditions were very rare in people with EDs [208].

**Cognitive functioning**

The literature included in RR regarding the cognitive changes in ED patients with AN following weight gain was sparse. It appears that some cognitive functions affected by EDs recover following nutritional restoration, whereas others persist. Cognitive functions, such as flexibility, central coherence, decision making, attention, processing speed and memory, are hypothesised to be impacted by, and influence the maintenance of EDs. A systematic review explored whether cognitive functions improved in AN following weight gain [83]. Weight gain appeared to be associated with improved processing speed in children and adolescents. However, no improvement was observed in cognitive flexibility following weight gain. Further, the results for adults were inconclusive [83].

**Reproductive health**

Infertility and higher rates of poor reproductive health are strongly associated with EDs, including miscarriages, induced abortions, obstetric complications, and poorer birth outcomes [84, 85]. Although amenorrhea is a known consequence of AN, oligomenorrhea (irregular periods) was common among individuals with BN and BED [86]. A twin study found women diagnosed with BN and BED were also more likely to have poly cystic ovarian syndrome (PCOS), leading to menstrual irregularities [209]. The prevalence of lifetime amenorrhea in this sample was 10.4%, and lifetime oligomenorrhea was 33.7%. An epidemiological study explored the association of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) in women with BN and BED and found prevalence rates as high as 42.4% for PMS and 4.2% for PMDD [210].

Given the increased rates of menstrual irregularities and issues, questions have been raised regarding whether this complication is reversed or improves with recovery. A review of five studies monitoring reproductive functions during recovery over a 6- to 18-year follow up period [211] noted no significant difference between the pooled odds of childbirth rates between the AN and general population—demonstrating that if patients undergo treatment for AN, achieve weight restoration, and continue to maintain wellness, reproductive functions can renormalise [211].

An observational study of women with AN, BN or EDNOS found higher rates of low birth rate, pre-term deliveries, caesarean deliveries, and intrauterine growth restrictions [84]. Increased caesarean delivery was also observed in a large cohort of women diagnosed with BED [212]. However, these women had higher birth weight babies [212]. Further, women with comorbid ED and epilepsy were found to have an increased risk of pregnancy-related comorbidities, including preeclampsia (gestational hypertension and signs of damage to the liver and kidneys), gestational diabetes and perinatal depression [213].

**Discussion**

The results from this review identified that the symptomology and outcomes of EDs are impacted by both psychiatric and medical factors. Further, EDs have a mortality rate substantially higher than the general population, with a significant proportion of those who die from an ED dying by suicide or as a result of severe medical complications.

This RR noted high rates of psychiatric and medical comorbidities in people with EDs, with comorbidities contributing to increased ED symptom severity, maintenance of some ED behaviours, compromised functioning, and adverse treatment outcomes. Evidence suggested that early identification and management of psychiatric and medical comorbidities in people with an ED may improve response to treatment and outcomes [29, 35, 83].

EDs and other psychiatric conditions often shared symptoms and high levels of psychopathology crossover were noted. The most prevalent psychiatric comorbidities were anxiety disorders, mood disorders and substance use disorders [8, 100, 119]. Perhaps unsurprising given the prevalence of these illnesses in the general population. Of concern is the elevated suicide rate noted across the ED spectrum, the highest observed in AN [58, 140, 149]. For people with AN, suicide attempts were mostly associated with comorbid mood and anxiety disorders [136]. The review noted elevated rates of NSSI were particularly associated with binge/purge subtype EDs [150], impulsivity and emotional dysregulation (again, an example of psychopathological overlap).

With regards to PDs, studies were limited to EDs with binge-purge symptomology. Of those included, the presence of a comorbid personality disorder and ED was associated with childhood trauma [110] and elevated mortality risk [111]. There appeared to be a
The RR highlighted the disproportionate lack of male
onstrating that males are not immune to ED symptoms,
more prevalent in females, research is increasingly dem -
derers) and changes in diagnostic criteria (including for
out of anxiety disorders and into newly defined chap -
sis, with the addition of new disorders (such as Autism
reorganisation (for example, moving OCD and PTSD
Spectrum Disorder and various Depressive Disorders),
DSM had significant implications for psychiatric diagno -
utilised in the RR search strategy, which included the
of Pica. These gaps could in part be due to the timeline
fied exploring the psychiatric and medical comorbidities
for ARFID, NES, and OSFED compared to that seen
the stark lack of research exploring the comorbidities for
ARFID, NES, and OSFED compared to that seen
with AN [53, 54] and ARFID [55].
EDs are complicated by medical comorbidities across
the neuroendocrine, skeletal, nutritional, gastrointestinal,
dental, and reproductive systems that can occur along-
side, or result from the ED. The RR noted mixed evidence
regarding the effectiveness and safety of enteral feeding
[180, 181], with some studies noting that RFS could be
safely managed with supplementation [191]. Research
also described the impacts of restrictive EDs on BMD
and binge eating behaviour on metabolic disorders [78,
195]. Purging behaviours, particularly self-induced vom -
ititing [79], were found to increase the risk of tooth erosion
[81] and damage to soft tissue within the gastrointestinal
tract [206]. Further, EDs were associated with a range of
reproductive health issues in women, including infertility
and birth complications [84].
Whilst the RR achieved its aim of synthesising a broad
scope of literature, the absence of particular ED diag-
oses and other key research gaps are worth noting. A
large portion of the studies identified focused on AN, for
both psychiatric and medical comorbidities. This reflects
the stark lack of research exploring the comorbidities for
ARFID, NES, and OSFED compared to that seen
with AN, BN and BED. There were no studies identi-
fied exploring the psychiatric and medical comorbidities
of Pica. These gaps could in part be due to the timeline
utilised in the RR search strategy, which included the
transition from DSM-IV to DSM-5. The update in the
DSM had significant implications for psychiatric diagno-
sis, with the addition of new disorders (such as Autism
Spectrum Disorder and various Depressive Disorders),
reorganisation (for example, moving OCD and PTSD
out of anxiety disorders and into newly defined chap -
ters) and changes in diagnostic criteria (including for
AN and BN, and establishing BED as a discrete disor-
der). Although current understanding suggests EDs are
more prevalent in females, research is increasingly dem-
onstrating that males are not immune to ED symptoms,
and the RR highlighted the disproportionate lack of male
subjects included in recent ED research, particularly in
the domain of psychiatric and medical comorbidities.
As the RR was broad in scope and policy-driven in
intent, limitations as a result of this methodology ought
to be considered. The RR only considered ‘Western’
studies, leading to the potential of important pieces of
work not being included in the synthesis. In the interest
of achieving a rapid synthesis, grey literature, qualita-
tive and theoretical works, case studies or implementa-
tion research were not included, risking a loss of nuance
in developing fields, such as the association and preva-
ence of complex/developmental trauma with EDs (most
research on this comorbidity focuses on PTSD, not com-
plex or developmental trauma) or body image dissatisfac-
tion among different gender groups. No studies regarding
the association between dissociative disorders and EDs
were included in the review. However, dissociation can
co-occur with EDs, particularly AN-BP and among those
with a trauma history [214]. Future studies would benefit
from exploring this association further, particularly as
trauma becomes more recognised as a risk factor for ED
development.
The review was not designed to be an exhaustive sum-
mary of all medical comorbidities. Thus, some areas of
medical comorbidity may not be included, or there may
be variability in the level of detail included (such as, lim-
ited studies regarding the association between cancer
and EDs). Studies that explored the association between
other autoimmune disorders (such as Type 1 Diabetes,
Crohn’s disease, Addison’s disease, ulcerative colitis, and
coeliac disease) and EDs [215, 216] were not included.
Future reviews and research should examine the asso-
ciations between autoimmune disorders and the subse-
quent increased risk of EDs, and likewise, the association
between EDs and the subsequent risk of autoimmune
disorders.
An important challenge for future research is to explore
the impact of comorbidity on ED identification, develop-
ment and treatment processes and outcomes. Insights
could be gained from exploring shared psychiatric symp-
tomology (i.e., ARFID and ASD, BN/BED and personality
disorders, and food addiction). Particularly in disorders
where the psychiatric comorbidity appears to precede
the ED diagnosis (as may be the case in anxiety disorders
[28]) and the unique physiological complications of these
EDs (e.g., the impact of ARFID on childhood develop-
ment and growth). Further, treatment outcomes would
benefit from future research exploring the nature of the
proposed reciprocal nature between EDs and comor-
bidities, particularly in those instances where there is sig-
nificant shared psychopathology, or the presence of ED
symptoms appears to exacerbate the symptoms of the
other condition—and vice versa.
The majority of research regarding the newly introduced EDs has focused on understanding their aetiology, psychopathology, and what treatments demonstrate efficacy. Further, some areas included in the review had limited included studies, for example cancer and EDs. Thus, in addition to the already discussed need for further review regarding the association between EDs and autoimmune disorders, future research should explore the nature and prevalence of comorbidity between cancers and EDs. There was variability regarding the balance of child/adolescent and adult studies across the various comorbidities. Some comorbidities are heavily researched in child and adolescent populations (such as refeeding syndrome) and others there is stark child and adolescent inclusion, with included studies only looking at adult samples. Future studies should also address specific comorbidities as they apply to groups underrepresented in current research. This includes but is not limited to gender, sexual and racial minorities, whereby prevalence rates of psychiatric comorbidities are elevated. [88] In addition, future research would benefit from considering the nature of psychiatric and medical comorbidity for subthreshold and subclinical EDs, particularly as it pertains to an opportunity to identify EDs early within certain comorbidities where ED risk is heightened.

Conclusions
This review has identified the psychiatric and medical comorbidities of EDs, for which there is a substantial level of literature, as well as other areas requiring further investigation. EDs are associated with a myriad of psychiatric and medical comorbidities which have significant impacts on the symptomology and outcomes of an already difficult to treat, and burdensome illness.

Abbreviations
ADHD: Attention deficit hyperactivity disorder; AN: Anorexia nervosa; AN-R: Anorexia nervosa—restricting type; AN-BP: Anorexia nervosa—binge-purge type; ARFID: Avoidant restrictive food intake disorder; ASD: Autism spectrum disorder; BED: Binge eating disorder; BMI: Body mass index; BN: Bulimia nervosa; BPD: Borderline personality disorder; DSM-5: Diagnostic and statistical manual of mental disorders, 5th edition; ED: Eating disorder; GAD: Generalised anxiety disorder; ICD-11: International classification of diseases, 11th edition; MDD: Major depressive disorder; NES: Night eating syndrome; OSFED: Other specified feeding or eating disorder; PTSD: Post-traumatic stress disorder; RR: Rapid review.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s40337-022-00654-2.

Acknowledgements
The authors would like to thank and acknowledge the hard work of Healthcare Management Advisors (HMA) who were commissioned to undertake the Rapid Review. Additionally, the authors would like to thank all members of the consortium and consultation committees for their advice, input, and considerations during the development process. Further, a special thank you to the carers, consumers and lived experience consultants that provided input to the development of the Rapid Review and wider national Eating Disorders Research & Translation Strategy. Finally, thank you to the Australian Government—Department of Health for their support of the current project.

National Eating Disorder Research Consortium: Phillip Anuad, Sarah Barakat, Robert Boakes, Leah Brennan, Emma Bryant, Susan Byrne, Belinda Caldwell, Shannon Calvert, Bronny Carroll, David Castle, Ian Caterson, Belinda Chelius, Lyn Chiem, Simon Clarke, Janet Coni, Lexi Crouch, Genevieve Dammery, Natasha Dzajkovski, Jasmine Fardoully, Carmen Felicia, John Fereley, Amber-Marie Finiolo, Nasim Foroughi, Mathew Fuller-Tyszkievicz, Anthea Fursland, Veronica Gonzalez-Arce, Bethanne Gouldthorp, Kelly Griffin, Scott Griffiths, Ashlea Hambleton, Amy Hannigan, Mel Hart, Susan Hart, Philippa Hay, Ian Hickie, Francis Kay-Lambkin, Ross King, Michael Kohn, Ezya Koreshe, Isabel Krug, Anvi Le, Jake Linardon, Randall Long, Amanda Long, Sloane Madden, Sarah Maguire, Danielle Maloney, Peta Marks, Sian McLean, Tho Meddick, Jane Miskovic-Wheatley, Deborah Mitchison, Richard O’Kearey, Shu Hwa Ong, Roger Paterson, Susan Paxton, Melissa Pehlivan, Genevieve Pepin, Andrea Philipou, Judith Piccone, Rebecca Pinkus, Bronwyn Raykos, Paul Rhodes, Elizabeth Rieger, Sarah Rodan, Karen Rockett, Janice Russell, Haleyl Russell, Fiona Salter, Susan Sawyer, Beth Shelton, Urvasheen Singh, Sophie Smith, Evelyn Smith, Karen Spielman, Sarah Squire, Juliette Thomson, Marika Tiggemann, Stephen Touyz, Ranjani Upatila, Lenny Vartanian, Andrew Wallis, Warren Ward, Sarah Wels, Eleanor Wertheim, Simon Wilksch & Michelle Williams.

Author contributions
DM, PM, ST and SM oversaw the Rapid Review process; AL carried out and wrote the initial review; AH and GP wrote the first manuscript; all authors edited and approved the final manuscript.

Funding
The RR was in-part funded by the Australian Government Department of Health in partnership with other national and jurisdictional stakeholders. As the organisation responsible for overseeing the National Eating Disorder Research & Translation Strategy, InsideOut Institute commissioned Healthcare Management Advisors to undertake the RR as part of a larger, ongoing project. Role of Funder: The funder was not directly involved in informing the development of the current review.

Availability of data and materials
Not applicable—all citations provided.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
ST receives royalties from Hogrefe and Huber, McGraw Hill and Taylor and Francis for published books/book chapters. He has received honoraria from the Takeda Group of Companies for consultative work, public speaking engagements and commissioned reports. He has chaired their Clinical Advisory Committee for Binge Eating Disorder. He is the Editor in Chief of the Journal of Eating Disorders. ST is a committee member of the National Eating Disorders Collaboration as well as the Technical Advisory Group for Eating Disorders. AL undertook work on this RR while employed by HMA. A/Prof Sarah Maguire is a guest editor of the special issue “Improving the future by understanding the present: evidence reviews for the field of eating disorders.”

Author details
1 InsideOut Institute, Central Clinical School, Faculty of Medicine and Health, Charles Perkins Centre (D17), University of Sydney, Camperdown, NSW 2006,
1. Brandsma L. Eating disorders across the lifespan. J Women Aging. 2007;19(1–2):155–72.

2. van Hoeken D, Hoek HW. Review of the burden of eating disorders: mortality, disability, costs, quality of life, and family burden. Curr Opin Psychiatry. 2020;33(6):521–7.

3. Weigel A, Lowe B, Kohlmann S. Severity of somatic symptoms in outpatients with anorexia and bulimia nervosa. Eur Eat Disord Rev. 2019;27(2):195–204.

4. Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007;61(3):348–58.

5. Jahraus J. Medical complications of eating disorders. Psychiatr Ann. 2018;48(10):163–7.

6. Ulfvebrand S, Birgegård A, Norling C, Högdahl L, von Hausswolff-Juhlin Y. Psychiatric comorbidity in women and men with eating disorders results from a large clinical database. Psychiatry Res. 2015;230(2):294–9.

7. Sachs KV, Harmke B, Mehler PS, Krantz MJ. Cardiovascular complications of anorexia nervosa: a systematic review. Int J Eat Disord. 2016;49(3):238–48.

8. Smith AR, Zuromski KL, Dodd DR. Eating disorders and suicidality: what we know, what we don’t know, and suggestions for future research. Curr Opin Psychol. 2018;22:63–7.

9. Arcelus J, Mitchell AJ, Wiles J, Nielsen S. Mortality rates in patients with anorexia nervosa and other eating disorders: a meta-analysis of 36 studies. Arch Gen Psychiatry. 2011;68(7):724–31.

10. Mayes SD, Fernandez-Mendoza J, Baweja R, Calhoun S, Mahr F, Aggarwal R, et al. Correlates of suicide ideation and attempts in children and adolescents with eating disorders. Eat Disord. 2014;22(4):352–66.

11. Hart LM, Granillo MT, Jorm AF, Paxton SJ. Unmet need for treatment in the eating disorders: a systematic review of eating disorder specific treatment seeking among community cases. Clin Psychol Rev. 2011;31(5):727–35.

12. Kaplan AS, Garfinkel PE. Difficulties in treating patients with eating disorders: A review of patient and clinician variables. Can J Psychiatry. 1999;44(7):665–70.

13. Eddy KT, Tabin N, Thomas JJ, Murray HB, Keshvavidh A, Hastings E, et al. Recovery from anorexia nervosa and bulimia nervosa at 22-year follow-up. J Clin Psychiatry. 2017;78(2):184–9.

14. John A, Marchant A, Demmler J, Tan J, DellPozo-Banos M. Clinical management and mortality risk in those with eating disorders and self-harm: e-cohort study using the SAIL databank. BJPsych Open. 2021;7(2):1–8.

15. Monteleone P, Brambilla F. Multiple comorbidity in people with eating disorders: In: Comorbidity of mental and physical disorders. vol. 179. Karger Publishers, 2015. p. 56–80.

16. Van Alsten SC, Duncan AE. Lifetime patterns of comorbidity in eating disorders: an approach using sequence analysis. Eur Eat Disord Rev. 2020;28(6):709–23.

17. National Institute of Health and Care Excellence. Managing comorbid health problems in people with eating disorders. United Kingdom: National Institute of Health and Care Excellence. 2019.

18. Institute InsideOut. Australian Eating Disorders Research and Translation Strategy 2021–2031. Sydney: The University of Sydney; 2021.
disorders: a meta-analysis. Eat Weight Disord Stud Anorex Bulim Obes. 2017;22(2):201–9.

42. Vrabel KR, Ro Ø, Martinsen EW, Hoffart A, Rosenvinge JH. Five-year prospective study of personality disorders in adults with longstanding eating disorders. Int J Eat Disord. 2010;43(1):122–8.

43. Bahji A, Mazhar MN, Hudson CC, Nadkarni P, MacNeil BA, Hawkson E. Prevalence of substance use disorder comorbidity among individuals with eating disorders: A systematic review and meta-analysis. Psychiatry Res. 2019;273:58–66.

44. Calero-Elvira A, Krug I, Davis K, Lopez C, Fernández-Arandá F, Treasure J. Meta-analysis on drugs in people with eating disorders. Eur Eat Disord Rev Prof J Eat Disord Assoc. 2009;17(4):243–59.

45. Palmese LB, Ratliff JC, Reutenauer EL, Tonizzo KM, Grilo CM, Tek C. Prevalence of night eating in obese individuals with schizophrenia and schizoaffective disorder. Compr Psychiatry. 2013;54(3):276–81.

46. Hartmann AS, Greenberg JL, Wilhelm S. The relationship between anorexia nervosa and body dysmorphic disorder. Clin Psychol Rev. 2013;33(3):675–85.

47. Kaisari P, Dourish CT, Higgs S. Attention deficit hyperactivity disorder (ADHD) and disordered eating behaviour: a systematic review and a framework for future research. Clin Psychol Rev. 2017;53:109–21.

48. Nazar BP, Bernardes CP, Peachey G, Sergeant J, Mattos P, Treasure J. The risk of eating disorders comorbid with attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Int J Eat Disord. 2016;49(12):1045–57.

49. Setz J, Kahraman-Lanzerath B, Legenbauer T, Sarrar L, Herpertz S, Salbach-Andrae H, et al. The role of impulsivity, inattention and comorbid ADHD in patients with bulimia nervosa. PLoS ONE. 2013;8(3):e63891.

50. Zibrovskis H, Brewerton TD, Duncan AE. Associations between ADHD and eating disorders in relation to comorbid psychiatric disorders in a nationally representative sample. Psychiatry Res. 2018;260:53–9.

51. Beck JR, DeBate RD, Olivardia R. The comorbidity of ADHD and eating disorders in a nationally representative sample. J Behav Health Serv Res. 2015;42(4):437–51.

52. Huke V, Turk J, Saeedi S, Kent A, Morgan JF. Autism spectrum disorders in eating disorder populations: a systematic review. Eur Eat Disord Rev. 2013;21(5):345–51.

53. Westwood H, Mandy W, Tchanturia K. Clinical evaluation of autistic symptoms in women with anorexia nervosa. Mol Autism. 2017;8(1):1–9.

54. Dell’Osso L, Carpta B, Gesi C, Cremone I, Corsi M, Massimetti E, et al. Subthreshold autism spectrum disorder in patients with eating disorders. Compr Psychiatry. 2018;81:66–72.

55. Dovey TM, Kumari V, Blissett J. Eating behaviour, behavioural problems and sensory profiles of children with avoidant/restrictive food intake disorder (ARFID), autistic spectrum disorders or picky eating: same or different? Eur Psychiatry. 2019;61:56–62.

56. Mitchell KS, Singh S, Hardin S, Thompson-Brenner H. The impact of comorbid posttraumatic stress disorder on eating disorder treatment outcomes: investigating the unified treatment model. Int J Eat Disord. 2021;54(7):1260–9.

57. Mitchell KS, Scoioli ER, Galovski T, Belfer PL, Cooper Z. Posttraumatic stress disorder and eating disorders: maintaining mechanisms and treatment targets. Eat Disord. 2021;29(3):292–306.

58. Goldstein A, Gvion Y. Socio-demographic and psychological risk factors for suicidal behavior among individuals with anorexia and bulimia nervosa: a systematic review. J Affect Disord. 2019;245:1149–67.

59. Pisetsy EM, Peterson CB, Mitchell JE, Wonderlich SA, Crosby RD, Le Grange D, et al. A comparison of the frequency of familial suicide attempts across eating disorder diagnoses. Int J Eat Disord. 2017;50(6):707–10.

60. Thornton LM, Welch E, Munn-Chernoff MA, Lichtenstein P, Bullik CM. Anorexia nervosa, major depression, and suicide attempts: shared genetic factors. Suicide Life Threat Behav. 2016;46(5):525–34.

61. Yao S, Kuja-Halkola R, Thornton LM, Runfola CD, D’Onofrio BM, Almqvist V. Gender and age differences in cardiovascular complications in anorexia nervosa patients. Int J Cardiol. 2017;227:55–7.

62. Karamanis G, Skalkidou A, Tsakonas G, Brandt L, Ebkorn A, Ekselius L, et al. Cancer incidence and mortality patterns in women with anorexia nervosa. Int J Cancer. 2014;134(7):1751–7.

63. Hofman M, Landewé-Cleuren S, Wojciechowski F, Kruseman AN. Prevalence and clinical determinants of low bone mineral density in anorexia nervosa. Eur J Intern Med. 2009;20(1):80–4.

64. Robinson L, Aldridge V, Clark E, Misra M, Micali N. A systematic review and meta-analysis of the association between eating disorders and bone density. Osteoporos Int. 2016;27(6):1953–66.

65. Rizzo SM, Douglas JW, Lawrence JC. Enteral nutrition via nasogastric tube for refeeding patients with anorexia nervosa: a systematic review. Nutr Clin Pract. 2019;34(3):359–70.

66. Cioffi I, Ponzo V, Pellegrini M, Evangelista A, Bioletto F, Ciccone G, et al. The incidence of the refeeding syndrome: A systematic review and meta-analyses of literature. Clin Nutr. 2021;40(6):3688–701.

67. Golden NH, Keane-Miller C, Sainani KL, Kapahphn CJ. Higher caloric intake in hospitalized adolescents with anorexia nervosa is associated with reduced length of stay and no increased rate of refeeding syndrome. J Adolesc Health. 2013;53(5):573–8.

68. Garber AK, Mauldin K, Michiata N, Buckelew SM, Shafer M-A, Moscicki A-B. Higher calorie diets increase rate of weight gain and shorten hospital stay in hospitalized adolescents with anorexia nervosa. J Adolesc Health. 2013;53(5):579–84.

69. O’Connor G, Nicholls D, Hudson L, Singhal A. Refeeding low weight hospitalized adolescents with anorexia nervosa: a multicenter randomized controlled trial. Nutr Clin Pract. 2016;31(5):681–9.

70. Raeuvouu A, Suokas J, Haakka J, Gissler M, Linna M, Grainger M, et al. Highly increased risk of type 2 diabetes in patients with binge eating disorder and bulimia nervosa. Int J Eat Disord. 2015;48(6):555–62.

71. Conviser JH, Fisher SD, Mitchell KB. Oral care behavior after purging in a sample of women with bulimia nervosa. J Am Dent Assoc. 2014;145(4):352–4.

72. Hermott AR, Oliveira PA, Martins CC, Paiwa SM, Pordeus IA, Auad SM. Tooth erosion and eating disorders: a systematic review and meta-analysis. PLoS ONE. 2014;9(11):e111123.

73. Hermott AR, Pordeus IA, Paiwa SM, Abreu MHN, Auad SM. Eating disorder risk behavior and dental implications among adolescents. Int J Eat Disord. 2013;46(7):677–83.

74. Peebles R, Sieke EH. Medical complications of eating disorders in youth. Child Adolesc Psychiatr Clin. 2019;28(4):593–615.

75. Hemmingsen SD, Wesselhoeft R, Lichtenstein MB, Støvring RK. Cognitive improvement following weight gain in patients with anorexia nervosa: a systematic review. Eur Eat Disord Rev. 2021;29(3):402–26.

76. Pasternak Y, Wantzbauf AF, Shoham-Vardi I, Serenjkio R, Guej J, Wizkabi A, et al. Obstetric and perinatal outcomes in women with eating disorders. J Women's Health. 2012;21(16):61–5.
126. Beilharz F, Castle D, Grace S, Rossell S. A systematic review of visual processing and associated treatments in body dysmorphic disorder. Acta Psychiatr Scand. 2017;136(1):16–36.

127. Svedlund NE, Norring C, Ginsberg Y, von Hausswolff-Juhlin Y. Symptoms of attention deficit hyperactivity disorder (ADHD) among adult eating disorder patients. BMC Psychiatry. 2017;17(1):9–11.

128. Brewerton TD, Duncan AE. Associations between attention deficit hyperactivity disorder and eating disorders by gender: results from the national comorbidity survey replication. Eur Eat Disord Rev. 2016;24(6):536–40.

129. Bisset M, Rinehart N, Sciberras E. DSM-5 eating disorder symptoms in adolescents with and without attention-deficit/hyperactivity disorder: a population-based study. Int J Eat Disord. 2019;52(7):855–62.

130. Svedlund NE, Norring C, Ginsberg Y, von Hausswolff-Juhlin Y. Are treatment results for eating disorders affected by ADHD symptoms? A one-year follow-up of adult females. Eur Eat Disord Rev. 2018;26(4):337–45.

131. Brewerton TD, Perlman MM, Gavidia I, Suro G, Genet J, Bunnell DW. The association of traumatic events and posttraumatic stress disorder with greater eating disorder and comorbid symptom severity in residential eating disorder treatment centers. Int J Eat Disord. 2020;53(12):2061–6.

132. Bühren K, Schwarte R, Fluck F, Timmesfeld N, Krei M, Egberts K, et al. Comorbid psychiatric disorders in female adolescents with first-onset anorexia nervosa. Eur Eat Disord Rev. 2014;22(1):39–44.

133. Guillame S, Jaussent O, Le S, Genty C, Bringer J, Couturier P, et al. Characteristics of suicide attempts in anorexia and bulimia nervosa: a case–control study. PLoS ONE. 2011;6(8):e23578.

134. Udo T, Bitley S, Grilo CM. Suicide attempts in US adults with lifetime DSM-5 eating disorders. BMC Med. 2019;17(1):1–13.

135. Duffy ME, Henkel KE, Joiner TE. Prevalence of self-injurious thoughts and behaviors in transgender individuals with eating disorders: a national study. J Adolesc Health. 2019;64(4):461–6.

136. Goel NJ, Sadeh-Shavit S, Flatt RE, Trockel M, Balantekin KN, Fitzsimmons-Craft EE, et al. Correlates of suicidal ideation in college women with eating disorders. Int J Eat Disord. 2018;51(6):579–84.

137. Sagiv E, Gvion Y. A multi factorial model of self-harm behaviors in Anorexia nervosa and Bulimia nervosa. Compr Psychiatry. 2020;96:152142.

138. Andersén M, Birgegård A. D iagnosis-specific self-image predicts longitudinal suicidal ideation in adult eating disorders. Int J Eat Disord. 2017;50(8):970–8.

139. Runfola CD, Thornton LM, Pisetsky EM, Bulik CM, Birgegård A. Self-image and suicide in a Swedish national eating disorders clinical register. Compr Psychiatry. 2014;55(3):439–49.

140. Forcano L, Álvarez E, Santamaría JJ, Jimenez-Murcia S, Granero R, Penelo E, et al. Suicide attempts in anorexia nervosa subtypes. Compr Psychiatry. 2015;63:123–30.

141. Bodell LP, Joiner TE, Keel PK. Comorbidity-independent risk for suicidal behavior increases with bulimia nervosa but not with anorexia nervosa. J Psychiatr Res. 2013;47(5):617–21.

142. Forcano L, Fernández-Aranza F, Álvarez-Moya E, Bulik C, Granero R, Gratosco M, et al. Suicide attempts in bulimia nervosa: personality and psychopathological correlates. Eur Psychiatry. 2009;24(2):91–7.

143. Huus C, Godart N,aille A, Pham-Scottez A, Foulon C, Divac SM, et al. Mortality and its predictors in severe bulimia nervosa patients. Eur Eat Disord Rev. 2013;21(11):15–9.

144. Crow SJ, Swanson SA, Le Grange D, Feig EH, Merikangas KR. Suicidal behavior in adolescents and adults with bulimia nervosa. Compr Psychiatry. 2014;55(7):1534–9.

145. Pisetsky EM, Wonderlich SA, Crosby RD, Peterson CB, Mitchell JE, Engel SG, et al. Depression and personality traits associated with emotion dysregulation: correlates of suicide attempts in women with bulimia nervosa. Eur Eat Disord Rev. 2015;23(6):537–44.

146. Brown KL, Lallow JG, Mezuk B. The relationship between body mass index, binge eating disorder and suicidality. BMC Psychiatry. 2018;18(1):21–7.

147. Olatunji BO, Cox R, Ebsenat C, Wall D. Self-harm history predicts resistance to inpatient treatment of body shape aversion in women with eating disorders: The role of negative affect. J Psychiatr Res. 2015;65:37–46.

148. Pérez S, Ros MC, Follgato JL, Marco JH. Non-suicidal self-injury differentiates suicide ideators and attempters and predicts future suicide attempts in patients with eating disorders. Suicide Life Threat Behav. 2019;49(5):1220–31.

149. Smith KE, Hayes NA, Styer DM, Washburn JJ. Emotional reactivity in a clinical sample of patients with eating disorders and nonsuicidal self-injury. Psychiatry Res. 2017;257:519–39.

150. Claes L, Konsly ED, Muehlenkamp J, Kuppers P, Vandereycken W. The affect-regulation function of nonsuicidal self-injury in eating-disordered patients: which affect states are regulated? Compr Psychiatry. 2010;51(4):386–92.

151. Navarro-Haro MV, Weissman I, Botella C, García-Palacios A. The role of emotion regulation strategies and dissociation in non-suicidal self-injury for women with borderline personality disorder and comorbid eating disorder. Compr Psychiatry. 2015;63:123–30.

152. Giovannazzo S, Sukkar S, Rosa G, Zappi A, Bezante G, Balbi M, et al. Anorexia nervosa and heart disease: a systematic review. Eat Weight Disord Stud Anorex Bulim Obes. 2019;24(2):199–207.

153. Bucquoeugne A, Dousbo BS, Krzesinski J-M, Delaney P. Anorexia nervosa and the kidney. Am J Kidney Dis. 2012;60(2):299–307.

154. Benini L, Todesco T, Frulloni L, Dalle Grave R, Campagnola P, Agugiaro F, et al. Esophageal motility and symptoms in restricting and binge-eating/purging anorexia. Dig Liver Dis. 2010;42(11):767–72.

155. Gibson D, Watters A, Meher P. The intersect of gastrointestinal symptoms and malnutrition associated with anorexia nervosa and avoidant/restrictive food intake disorder: Functional or pathophysiologic? A systematic review. Int J Eat Disord. 2021.

156. Abraham S, Kellow J. Exploring eating disorder quality of life and functional gastrointestinal disorders among eating disorder patients. J Psychosom Res. 2011;70(4):372–7.

157. Brewster DH, Nowell SL, Clark DN. Risk of oesophageal cancer among patients previously hospitalised with eating disorder. Cancer Epidemiol. 2015;39(3):313–20.

158. Smith KR, Moran TH. Gastrointestinal peptides in eating-related disorders. Physiol Behav. 2021;238:113456.

159. Seidel M, Markmann Jensen S, Healy D, Dureya A, Watson HJ, Holst B, et al. A systematic review and meta-analysis finds increased blood levels of all forms of ghrelin in both restricting and binge-eating/purging subtypes of anorexia nervosa. Nutrients. 2021;13(2):709.

160. Becker KA, Manuso C, Dreier MJ, Asanze E, Breithaupt L, Slattery M, et al. Esophageal and gastric symptoms and malnutrition associated with anorexia nervosa and avoidant/restrictive food intake disorder. Compr Psychiatry. 2013;54(7):769–81.

161. Calcif Tissue Int. 2021;110(5):562–75.

162. Zaina F, Persiani F, Persiani L, Capodaglio P, Negrisi S, Polli N. Prevalence of idiopathic scoliosis in anorexia nervosa patients: results from a cross-sectional study. J Spinal Disord Tech. 2018;31(3):168–73.

163. Calcif Tissue Int. 2021;110(5):562–75.

164. Avila JT, Park K, Golden NH. Eating disorders in adolescents with chronic gastrointestinal and endocrine diseases. Lancet Child Adolesc Health. 2019;3(3):181–9.

165. Ruusuen A, Rocks T, Jacka F, Loughman A. The gut microbiome in anorexia nervosa: relevance for nutritional rehabilitation. Psychopharmacology. 2019;236(5):1545–58.

166. Feng X, Persiani F, Persiani L, Capodaglio P, Negrisi S, Polli N. Prevalence of idiopathic scoliosis in anorexia nervosa patients: results from a cross-sectional study. J Spinal Disord Tech. 2018;31(3):168–73.

167. Heng C, Muñoz M, Shibli-Rahalla A. Anorexia nervosa and osteoporosis. Calcif Tissue Int. 2021;109(5):652–75.

168. Mumphord J, Kohn M, Brody J, Miskovic-Westley J, Madden S, Clarke S, et al. Long-term outcomes of adolescent anorexia nervosa on bone. J Adolesc Health. 2019;6(3):305–10.

169. Robinson L, Aldridge V, Clark EM, Misra M, Micali N. Pharmacological treatment options for low bone mineral density and secondary osteoporosis in anorexia nervosa: a systematic review of the literature. J Psychiatry. 2013;79(1):97–109.
with anorexia nervosa: A systematic review and meta-analyses. Int J Eat Disord. 2010;43(3):218–25.

171. Lebow J, Sim L. The influence of estrogen therapies on bone mineral density in premenopausal women with anorexia nervosa and amenorrhea. Vi tal Horm. 2013;92:243–57.

172. Maimoun L, Meenan gh E, Lawson EA, Misra M, Gleysteen S, Schoenfeld D, et al. Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2011;96(7):2081–8.

173. Bloch M, Ish-Shalom S, Greenman Y, Klein E, Latzer Y. Dehydroepiandrosterone treatment effects on weight, bone density, bone metabolism and mood in women suffering from anorexia nervosa—a pilot study. Psychiatry Res. 2012;200:344–9.

174. Vaijapeyam S, Ecklund K, Mulkenn R, Feldman HA, O'Donnell JM, Divasta AD, et al. Magnetic resonance imaging and spectroscopy evidence of efficacy for adrenal and gonadal hormone replacement therapy in anorexia nervosa. Bone. 2018;110:335–42.

175. Fazeli PK, Wang B, Miller KK, Herzog DB, Misra M, Lee H, et al. Teriparatide increases bone formation and bone mineral density in adult women with anorexia nervosa. J Clin Endocrinol Metab. 2014;99(4):1322–9.

176. Gioi lo A, Idolazzi L, Caimmi C, Fassio A, Bertoldo F, Dalle Grave R, et al. Vitamin D levels strongly influence bone mineral density and bone turnover markers during weight gain in female patients with anorexia nervosa. Int J Eat Disord. 2017;50(9):1041–9.

177. Davies JE, Cockfield A, Brown A, Corr J, Smith D, Munro C. The medical risks of severe anorexia nervosa during initial re-feeding and medical stabilisation. Clin Nutr ESPEN. 2017;17:92–9.

178. Hale MD, Logomarsino JV. The use of enteral nutrition in the treatment of eating disorders: a systematic review. Eat Weight Disord Stud Anorex Bulim Obses. 2019;24(2):179–98.

179. Rocks T, Pelly F, Wilkinson P. Nutrition therapy during initiation of refeeding in underweight children and adolescent inpatients with anorexia nervosa: a systematic review of the evidence. J Acad Nutr Diet. 2014;114(8):897–907.

180. Gentile MG, Pastorelli P, Ciceri R, Manna GM, Collimedaglia S. Specialized refeeding treatment for anorexia nervosa patients suffering from extreme undernutrition. Clin Nutr. 2010;29(5):627–32.

181. Hanachi M, Melchor JC, Crenn P. Hypertransaminasemia in severely malnourished adult anorexia nervosa patients: risk factors and evolution under enteral nutrition. Clin Nutr. 2013;32(3):391–5.

182. Rosen E, Sabel AS, Brzozowska M, Janaszek K, Małkowski P, et al. A ten-year longitudinal study of prevalence of eating disorders in the general polish type 2 diabetes population. Med Sci Monit Int Med J Exp Clin Res. 2018;24:9204.

183. Gallant A, Drapeau V, Allison KC, Tremblay A, Lambert M, O’Loughlin J, et al. Night eating behavior and metabolic health in mothers and fathers enrolled in the QUALITY cohort study. Eat Behav. 2014;15(2):186–91.

184. Hood MM, Reutrakul S, Crowley SJ. Night eating in patients with type 2 diabetes. Associations with glycem ic control, eating patterns, sleep, and mood. Appetite. 2014;79:1–6.

185. Udo T, McKee SA, White MA, Masheb RM, Barnes RD, Grilo CM. Menopause and metabolic syndrome in obese individuals with binge eating disorder. Eat Behav. 2014;15(2):182–5.

186. Kiesel S, Baghaie H, Lalloo R, Johnson NW. Association between poor oral health and eating disorders: systematic review and meta-analysis. Br J Psychi atry. 2015;207(4):299–305.

187. Pallier A, Karmova A, Bollot A, Colon P, Ringuet D, Bouchard P, et al. Dental and periodontal health in adults with eating disorders: a case-control study. J Dent. 2019;84:55–9.

188. Lundgren JD, Smith BM, Spresser C, Harkins P, Zolton L, Williams K. The relationship of night eating to oral health and obesity in community dental clinic patients. Age (Years). 2010;37(5):12.

189. Lundgren JD, Williams KB, Heitmann BL. Nocturnal eating predicts tooth loss among adults: results from the Danish MONICA study. Eat Behav. 2010;11(3):170–4.

190. Panico R, Piemonte E, Lazos J, Gilligan G, Zampini A, Lanfranchi H. Oral mucosal lesions in anorexia nervosa, bulimia nervosa and EDNOS. J Psychiatr Res. 2018;96:178–82.

191. Setnick J. Micronutrient deficiencies and supplementation in anorexia and bulimia nervosa: a review of literature. Nutr Clin Pract. 2010;25(2):137–42.

192. Oudman E, Wijnia JW, Oey MJ, van Dam MJ, Postma A. Preventing Wernicke’s encephalopathy in anorexia nervosa: A systematic review. Psychiatry Clin Neurosci. 2018;72(10):774–9.

193. Álégars M, Huang L, Von Holle AF, Peat CM, Thornton LM, Lichtenstein D. Association between premenstrual syndrome and premenstrual dysphoric disorder with bulimia nervosa and binge-eating disorder in a nationally representative epidemiological sample. Int J Eat Disord. 2016;49(7):841–50.
review and meta-analysis of long-term follow-up studies. Diseases. 2020;8(4):46.

212. Bulik CM, Von Holle A, Siega-Riz AM, Torgersen L, Lie KK, Hamer RM, et al. Birth outcomes in women with eating disorders in the Norwegian Mother and Child cohort study (MoBa). Int J Eat Disord. 2009;42(1):9–18.

213. Kolstad E, Gilhus NE, Veby G, Reiter SF, Lossius MI, Bjørk M. Epilepsy and eating disorders during pregnancy: prevalence, complications and birth outcome. Seizure. 2015;28:81–4.

214. Longo P, Panero M, Amodeo L, Demarchi M, Abbate-Daga G, Marzola E. Psychoform and somatoform dissociation in anorexia nervosa: a systematic review. Clin Psychol Psychother. 2021;28(2):295–312.

215. Zerwas S, Larsen JT, Petersen L, Thornton LM, Quaranta M, Koch SV, et al. Eating disorders, autoimmune, and autoinflammatory disease. Pediatrics. 2017;140(6):e20162089.

216. Wotton CJ, James A, Goldacre MJ. Coexistence of eating disorders and autoimmune diseases: record linkage cohort study, UK. Int J Eat Disord. 2016;49(7):663–72.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.